Research brief · 2026-09-09
What Does CJC-1295 Actually Do? What the Research Shows
CJC-1295 is a synthetic, chemically modified version of growth hormone releasing hormone, or GHRH, the natural signal the hypothalamus sends to the pituitary gland to release growth hormone. The natural hormone breaks down within minutes; the modifications make CJC-1295 more stable. It is not approved as a medicine anywhere.
The detail that matters more here than for most peptides is that two different molecules are sold under this one name. "CJC-1295 with DAC" is attached to a small molecule that binds albumin, a blood protein, stretching its effect from minutes to days. "CJC-1295 without DAC", also sold as Modified GRF 1-29, lacks that attachment and behaves like a short-acting GHRH analog. Nearly all the human research tested the DAC version; products sold today are often the version without it.
The DAC studies are real but small. Teichman and colleagues, in the Journal of Clinical Endocrinology and Metabolism in 2006, ran randomized, placebo-controlled Phase 1 studies in healthy adults. Injections raised growth hormone and IGF-1 for roughly a week or more after a single dose, in a dose-dependent way, with no serious adverse reactions reported over the study period. A 2006 study by Ionescu and Frohman found the pituitary's natural pulsing pattern of growth hormone persisted during continuous stimulation.
Only one CJC-1295 trial is registered on ClinicalTrials.gov: a Phase 2 study in 120 people with HIV-associated visceral obesity, sponsored by ConjuChem. It was terminated, and no results were ever posted. No human trial of any kind has tested CJC-1295 for muscle growth, fat loss or anti-aging in healthy adults.
So the limit is this: the version with human data measured hormone levels in small groups of volunteers over weeks, not any health outcome. The version most often sold has no dedicated human data at all. Long-term effects of either are unstudied. CJC-1295 is not approved for human use.
Sources
- Teichman SL et al., Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GHRH, in healthy adults
- Journal of Clinical Endocrinology & Metabolism 2006
- Ionescu M, Frohman LA, Pulsatile secretion of GH persists during continuous stimulation by CJC-1295
- Journal of Clinical Endocrinology & Metabolism 2006
- ClinicalTrials.gov NCT00267527, CJC-1295 in HIV-associated visceral obesity, ConjuChem, n=120, terminated, no results posted
- ClinicalTrials.gov
Peptide Proof reports what studies found. We do not give medical advice, dosing guidance, or treatment recommendations.